<DOC>
	<DOCNO>NCT02772627</DOCNO>
	<brief_summary>The purpose study investigate tolerability safety three multiple dose regimens nebicapone ( BIA 3-202 100 mg , 200 mg , 300 mg 6 time daily ) healthy volunteer . To characterise steady-state pharmacokinetic erythrocyte COMT inhibition profile nebicapone healthy volunteer .</brief_summary>
	<brief_title>Study Investigate Tolerability , Steady-state Pharmacokinetics Erythrocyte COMT Inhibition BIA 3-202</brief_title>
	<detailed_description>Study design methodology : This single centre , human pharmacology ( phase I ) , double-blind , randomised , placebo-controlled study three multiple rise dos three sequential group healthy volunteer . Subjects screen eligibility within 28 day admission . Screening : Screening consist review medical history , physical examination , neurological examination , vital sign , 12-lead ECG , clinical laboratory safety test ( haematology , coagulation , plasma biochemistry , urinalysis , HBsAg , anti-HCV Ab , anti-HIV-1 anti-HIV-2 Ab ) , drug abuse alcohol screen , write informed consent . A pregnancy test perform female subject . The investigator inform screening result prior subject 's admission . Treatment period : Eligible subject admit UFH one treatment period morning day prior receive first dose trial medication remain UFH least 48 hour receive final dose trial medication ( final dose : Day 8 ; leave UFH : Day 10 ) . Then , leave return Days 15 , 22 29 168 h , 336 h , 504 h post final dose blood sample clinical evaluation . Trial medication administer 4-h interval ( Group 1 : Nebicapone 100 mg/Placebo , 6 times/day ; Group 2 : Nebicapone 200 mg/Placebo , 6 times/day ; Group 3 : Nebicapone 300 mg/Placebo , 6 times/day ) . On admission ( Day -1 ) , subject physical examination , medical history update , vital sign ( blood pressure heart rate ) , neurological examination , 12-lead ECG , clinical laboratory test ( haematology , coagulation , plasma biochemistry , urinalysis ) , pregnancy test , screen drug abuse alcohol , 24-h urine collection assay urinary electrolyte creatinine . On Day 1 , Nebicapone /Placebo start administer 4 hourly interval , final dose Day 8 . The following assessment perform described : vital sign ( blood pressure heart rate ) Days 1 7 pre 1 hour post 08 , 12 , 16 , 20 24 h dos , Day 8 pre-dose 1 , 24 , 48 , 168 , 336 hour post final dose , Day 29 ; physical examination : admission , Day 10 Day 29 ; neurological examination admission , pre-dose 2 hour post 08 , 12 , 16 , 20 24 h dos Day 1 , 2 hour post 08h00 20h00 dos Days 2 7 , 2 hour post 08h00 dose Day 8 ; 12-lead ECG 1 hour post 08h00 dose Days 1 , 2 , 3 , 5 8 , 48 h post final dose , Day 29 ; continuous lead-II ECG monitoring 0-6 hour post first dose Day 1 , 0-4 hour post 08h00 dose Day 8 ; blood sample ( 7 ml ) assay plasma nebicapone metabolite , assay erythrocyte soluble COMT ( S-COMT ) activity take Day 1 , pre-dose , ½ , 1 , 1½ , 2 , 3 , 4 , 8 , 12 16 hour post first dose ( 08h00 ) , Day 8 , pre final dose ( 08h00 ) , ½ , 1 , 1½ , 2 , 3 , 4 , 6 , 8 , 12 , 16 , 24 , 36 , 48 , 168* , 336* , 504* hour post final dose ( *only assay plasma nebicapone metabolite ) , Days 2 , 3 , 4 , 5 , 6 , 7 , pre 08h00 20h00 dos ; urine blood collection urinalysis , coagulation , haematology plasma biochemistry admission , Days 2 , 10 29 ; 24-h urine collection assay urinary electrolyte creatinine admission , Days 1 9 . Adverse event monitor throughout . Follow-up : The end-of-study assessment take place last blood sample ( 504 h ) include : medical history review , physical examination , vital sign , 12-lead ECG , clinical laboratory safety test , adverse event ; pregnancy test ( female ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 28 kg/m2 , inclusive . Subjects healthy determine pre study medical history , physical examination , 12 lead ECG . Subjects clinical laboratory test acceptable investigator . Subjects negative HBsAg , antiHCV Ab HIV1 HIV2 Ab test screen . Subjects negative drug abuse alcohol screen admission . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . Subjects conform inclusion criterion , Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 21 unit alcohol week . Subjects significant infection know inflammatory process screen and/or admission . Subjects acute gastrointestinal symptom time screen and/or admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects acute infection influenza time screen and/or admission . Subjects use prescription drug within 4 week first dose . Subjects use oral contraceptive counter medication exclude oral routine vitamin include mega dose vitamin therapy within one week first dose . Subjects use investigational drug and/or participate clinical trial within 3 month first admission study . Subjects previously receive BIA 3202 . Subjects donate and/or receive blood blood product within previous 2 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method use oral contraceptive . Subjects unwilling unable give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Parkinson 's disease , Nebicapone</keyword>
</DOC>